- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01866384
Targeted Temperature Management After Intracerebral Hemorrhage
Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this randomized clinical trial, patients with IPH within 6 hours of onset will be randomized to one of two study arms. In one arm, patients will have 72 hours of TTM to MIH (32-34 degree Celcius). In the second arm, patients will have 72 hours of TTM to Normal Temperature (NT)(36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
Primary outcomes are examining the frequency of adverse events (AEs) that will be possibly or probably related to treatment. AEs will be assessed up to 15-days after admission or discharge if earlier and the frequency of severe adverse events (SAEs) that will be possibly and probably related to treatment.
SAEs will be assessed up to 90-days.
The secondary outcome measures will be in-hospital neurological deterioration between day 0-7 (decrease in GCS10 in ≥2 points, or increase in the NIHSS11 ≥4 points), in-hospital mortality, modified Rankin Score [mRS]12 at discharge and 90-days.
To determine whether TTM to MIH can limit HG and cerebral edema, will be examining absolute change in hematoma between baseline and 24 hours, new or absolute change in IVH between baseline and 24 hours, the proportion of patients with HG, absolute change in hemostatic proteins, the absolute change in cerebral edema between baseline and 24, 48,72, and 168-hours, relative change in cerebral edema.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jennifer Glendening, MSN, RN
- Phone Number: 215-955-7962
- Email: jennifer.glendening@jefferson.edu
Study Contact Backup
- Name: John Furlong, RN,CCRC
- Phone Number: 215-955-7301
- Email: john.furlong@jefferson.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Contact:
- Meghan Wakefield, RN,CCRP
- Phone Number: 215-503-9110
- Email: meghan.wakefield@jefferson.edu
-
Principal Investigator:
- Fred Rincon, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- spontaneous supratentorial IPH documented by CT scan within 6 hours after the onset of symptoms and admission to the Neuro-ICU,
- baseline hematoma >15cc with or without IVH
- need for mechanical ventilation
Exclusion Criteria:
- GCS <6
- age <18 years
- pregnancy
- pre-morbid mRS>2
- Do Not Resuscitate (DNR) order "prior" to enrollment
- uncontrolled bleeding of different etiology (trauma, gastro-intestinal bleeding [UGIB/LGIB]
- planned surgical decompression within 24 hours
- secondary causes of IPH (ischemic stroke, coagulopathy [INR>1.4, aPTT> 1.5 times baseline, thrombocytopenia platelets <100,000/uL], trauma, AVM, aneurysm, cerebral sinus thrombosis, or other causes)
- evidence of sepsis
- inability to obtain written informed consent
- participation in another trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Normal Temperature
72 hours of Normal Temperature (36-37 degrees Celcius).
Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
|
In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
|
Experimental: Mild Induced Hypothermia
72 hours of mild induced hypothermia (32-34 degrees Celcius).
Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
|
Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control).
In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events (AEs) that will be possibly or probably related to the treatment.
Time Frame: Continuous throughout 3 year study period
|
To determine whether TTM to MIH is safe and tolerable after IPH measured by the frequency of adverse events (AEs) that will be possibly or probably related to the treatment.
|
Continuous throughout 3 year study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital neurological deterioration between day 0-7.
Time Frame: Continuous throughout 3 year study period
|
To determine whether TTM to MIH can limit hematoma growth and cerebral edema measured by in-hospital neurological deterioration between day 0-7.
|
Continuous throughout 3 year study period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fred Rincon, MD, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12D.466
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypothermia
-
RECIO PÉREZ, JESÚSUniversity of AlcalaCompletedHypothermia; Anesthesia | Hypothermia Following Anesthesia | Hypothermia Following Anesthesia, Sequela | Hypothermia Due to AnestheticSpain
-
The University of Texas Health Science Center,...RecruitingHypothermia; Anesthesia | Hypothermia, Newborn | Hypothermia, SequelaUnited States
-
Michael Garron HospitalCompletedHypothermia | Body Temperature Changes | Hypothermia Following Anesthesia | Hypothermia, Accidental | Hypothermia Due to AnestheticCanada
-
Centre Leon BerardCompletedHypothermia | Hypothermia; Anesthesia | Hypothermia, AccidentalFrance
-
Marmara UniversityCompletedHypothermia; Anesthesia | Hypothermia Following AnesthesiaTurkey
-
Marmara UniversityCompletedHypothermia; Anesthesia | Hypothermia Following AnesthesiaTurkey
-
Ciusss de L'Est de l'Île de MontréalCompletedHypothermia Following Anesthesia | Hypothermia, AccidentalCanada
-
Ankara Diskapi Training and Research HospitalCompletedPreventing Hypothermia | Perioperative HypothermiaTurkey
-
Universitat Internacional de CatalunyaRecruitingHypothermia | Hypothermia; Anesthesia | Hypothermia, AccidentalSpain
-
Universitair Ziekenhuis BrusselCompletedChildren | Hypothermia; Anesthesia | Hypothermia Following AnesthesiaBelgium
Clinical Trials on Normal Temperature
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical UniversityRecruitingNecrotizing Enterocolitis | Bloody Stool | Neutral TemperatureChina
-
Ege UniversityCompletedPrematurity | Feeding Disorder NeonatalTurkey
-
Karolinska InstitutetDanderyd Hospital; Stockholm South General HospitalWithdrawnSepsis | Critical Illness | Fluid Overload | Hemodynamic InstabilitySweden
-
Ajou University School of MedicineCompletedTrauma | Core TemperatureKorea, Republic of
-
University of BonnDLR German Aerospace CenterCompletedResting Energy ExpenditureGermany
-
Poitiers University HospitalCompletedContinuous Non Invasive Cutaneous Temperature | Zero Heat Flux Method | Esophageal Temperature | Arterial Temperature | Intracerebral TemperatureFrance
-
Ankara City Hospital BilkentCompletedHypothermia | Orthopedic Disorder | Hip ArthropathyTurkey
-
The University of Texas Health Science Center,...Zoll Medical Corporation; Vivian L. Smith Foundation for Neurologic ResearchTerminatedSubdural Hematoma, TraumaticUnited States, Japan
-
Malaghan Institute of Medical ResearchRecruitingLymphoma | Leukemia | Myeloma | Temperature Change, Body | Haematological MalignancyNew Zealand
-
Fudan UniversityNot yet recruitingCognitive Function | Cardiovascular System | Respiratory SystemChina